White Paper: Regulatory Roadblocks & Expeditions for Global Clinical Trials
Published October 2021
Abstract:
This white paper dives into the regulatory differences for clinical trials in the U.S., Canada, Australia, and China. Our paper highlights how each corresponding regulatory authority aids in expediting clinical trials or reducing roadblocks. Some incentives discussed include reducing application fees and reporting requirements.
Keywords: clinical trials, clinical research, regulation, manufacturing, New Drug Applications, FDA, Health Canada, NMPA, TGA, drug approval, regulatory expeditions, import
Click here to view White paper: Regulatory Roadblocks & Expeditions for Global Clinical Trials